These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

943 related articles for article (PubMed ID: 24508508)

  • 21. The Cytoprotective and Cytotoxic Functions of Autophagy in Response to mTOR Inhibitors.
    Elshazly AM; Elzahed AA; Gewirtz DA
    Front Biosci (Landmark Ed); 2024 Jun; 29(6):231. PubMed ID: 38940039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug discovery targeting the mTOR pathway.
    Martelli AM; Buontempo F; McCubrey JA
    Clin Sci (Lond); 2018 Mar; 132(5):543-568. PubMed ID: 29523752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From node to pathway blockade: lessons learned from targeting mammalian target of rapamycin.
    Hidalgo M
    J Clin Oncol; 2012 Jan; 30(1):85-7. PubMed ID: 22067403
    [No Abstract]   [Full Text] [Related]  

  • 24. Recent patents and patent applications relating to mTOR pathway.
    Liu X; Yue Z
    Recent Pat DNA Gene Seq; 2009; 3(1):44-52. PubMed ID: 19149738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapamycin as an antiaging therapeutic?: targeting mammalian target of rapamycin to treat Hutchinson-Gilford progeria and neurodegenerative diseases.
    Mendelsohn AR; Larrick JW
    Rejuvenation Res; 2011 Aug; 14(4):437-41. PubMed ID: 21851176
    [TBL] [Abstract][Full Text] [Related]  

  • 26.  Forever young?  Exploring the link between rapamycin, longevity and cancer.
    Van Meter M; Seluanov A; Gorbunova V
    Cell Cycle; 2012 Dec; 11(23):4296-7. PubMed ID: 23152185
    [No Abstract]   [Full Text] [Related]  

  • 27. Updates of mTOR inhibitors.
    Zhou H; Luo Y; Huang S
    Anticancer Agents Med Chem; 2010 Sep; 10(7):571-81. PubMed ID: 20812900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
    Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
    Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy.
    Tan J; Yu Q
    Chin J Cancer; 2013 Jul; 32(7):376-9. PubMed ID: 23668928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island.
    Arriola Apelo SI; Lamming DW
    J Gerontol A Biol Sci Med Sci; 2016 Jul; 71(7):841-9. PubMed ID: 27208895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is Rapamycin a Dietary Restriction Mimetic?
    Unnikrishnan A; Kurup K; Salmon AB; Richardson A
    J Gerontol A Biol Sci Med Sci; 2020 Jan; 75(1):4-13. PubMed ID: 30854544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapamycin in mice.
    Swindell WR
    Aging (Albany NY); 2017 Sep; 9(9):1941-1942. PubMed ID: 28876223
    [No Abstract]   [Full Text] [Related]  

  • 34. Targeting mTOR signaling by polyphenols: A new therapeutic target for ageing.
    Pazoki-Toroudi H; Amani H; Ajami M; Nabavi SF; Braidy N; Kasi PD; Nabavi SM
    Ageing Res Rev; 2016 Nov; 31():55-66. PubMed ID: 27453478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to.
    Blagosklonny MV
    Aging (Albany NY); 2012 May; 4(5):350-8. PubMed ID: 22683661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR in Lung Neoplasms.
    Krencz I; Sebestyen A; Khoor A
    Pathol Oncol Res; 2020 Jan; 26(1):35-48. PubMed ID: 32016810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic regulation, mitochondria and the life-prolonging effect of rapamycin: a mini-review.
    Pan Y; Nishida Y; Wang M; Verdin E
    Gerontology; 2012; 58(6):524-30. PubMed ID: 22947849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
    Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
    Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
    Zou Z; Chen J; Yang J; Bai X
    Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status and challenges associated with targeting mTOR for cancer therapy.
    Dowling RJ; Pollak M; Sonenberg N
    BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.